Form 8-K

8-K — Allarity Therapeutics, Inc.

Accession: 0001213900-26-046411

Filed: 2026-04-22

Period: 2026-04-21

CIK: 0001860657

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0287156-8k_allarity.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED APRIL 21, 2026 (ea028715601ex99-1.htm)

GRAPHIC (ea028715601_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0287156-8k_allarity.htm · Sequence: 1

false

0001860657

2026-04-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported)

April 21, 2026

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41160

87-2147982

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including

area code)

Not applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

ALLR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Matters.

On April 21, 2026, Allarity Therapeutics, Inc.

(the “Company”) announced the publication of two scientific posters being presented at the American Association for Cancer

Research (AACR) Annual Meeting 2026, held April 17–22 in San Diego, California. The Company’s press release is filed as Exhibit

99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Press Release, dated April 21, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Allarity Therapeutics, Inc.

Date: April 22, 2026

By:

/s/ Thomas H. Jensen

Thomas H. Jensen

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED APRIL 21, 2026

EX-99.1

Filename: ea028715601ex99-1.htm · Sequence: 2

Exhibit 99.1

Allarity Therapeutics Presents Two

AACR 2026 Posters Highlighting

Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data

Linking DRP®

and Overall Survival in Ovarian Cancer

- New AACR data

highlight stenoparib’s potential in colorectal cancer through WNT pathway modulation

- The Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer patients

- Posters now available on Allarity’s website

TARPON SPRINGS, Fla., April 21, 2026 –

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical

company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced

that it has published two scientific posters being presented at the American Association for Cancer Research (AACR) Annual Meeting 2026,

held April 17–22 in San Diego, California. Both are now available in the Scientific Publications section of the Company’s

website.

The two posters highlight new data supporting

stenoparib’s differentiated mechanism of action as well as the Company’s proprietary Drug Response Predictor (DRP®) for

stenoparib as a companion diagnostic platform.

Poster presentations

Poster 1

Title: A Drug Response Predictor (DRP®)

is associated with enhanced overall survival in the phase 2 trial in advanced, recurrent ovarian cancer patients treated twice daily with

2X-121/stenoparib (NCT03878849)

Session Title: Biomarkers Predictive of Therapeutic

Benefit 3

Session Time: April 20, 2026, 9:00 AM –

12:00 PM

This poster highlights clinical data demonstrating

that the highest stenoparib DRP® scores are associated with enhanced overall survival in patients treated with stenoparib, reinforcing

the value of DRP-based patient selection in ring-fencing those patients most likely to benefit from stenoparib.

Page 1 of 5

Poster 2

Title: 2X-121/stenoparib - a novel, dual inhibitor

of PARP and tankyrase in phase 2 clinical trials in advanced ovarian cancer - blocks the WNT signaling pathway and inhibits growth of

human colorectal cancer cell lines at clinically relevant drug concentrations

Session Title: Novel Antitumor Agents 2

Session Time: April 21, 2026, 9:00 AM –

12:00 PM

This poster presents new findings demonstrating

stenoparib’s unique mechanism of action to modulate the WNT/β-catenin signaling pathway and to inhibit the growth of colorectal

cancer cell lines at clinically relevant concentrations. Colon and rectal cancers remain among the most prevalent and deadly cancers in

the United States, with a high number of both new cases and cancer-related deaths each year, according to the National Cancer Institute,

underscoring the significant unmet medical need in this indication.

Chief Executive Officer of Allarity Therapeutics,

Thomas Jensen, commented:

“These new data highlight the potential

for stenoparib in one of the largest areas of unmet need in oncology—colorectal cancer—where we believe stenoparib’s

unique mechanism of action could make it a highly relevant therapy for this patient population. Moreover, based on insights from our ongoing

stenoparib clinical development, we believe our DRP® platform may play an important role in identifying those patients most likely

to achieve the outcomes we ultimately seek in cancer therapy: enhanced and extended survival with a favorable tolerability profile. It

is difficult to overstate the importance of this, as extended survival- especially from an easy-to-take oral therapy without the typical

toxicities of chemotherapy- addresses the most critical considerations for both patients and oncologists when selecting a particular therapy.”

Both posters are available on the Company’s

website under the Scientific Publications section.

Page 2 of 5

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule

dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic

targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been

implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s

unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, Small Cell Lung

Cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which

was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has two ongoing Phase 2 trial

protocols for stenoparib in Ovarian Cancer patients. In the first, patients who had had 2+ lines of therapy were enrolled on stenoparib

and given drug twice daily. This protocol has been closed to further enrollment but continues for the enrolled patients who are still

receiving benefit from stenoparib administration. The updated data from this study were presented at the AACR special conference on advances

in Ovarian Cancer in September 2025. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures.

An amended protocol designed expressly to capitalize on the emerging clinical experience with stenoparib in platinum resistant patients

began enrolling patients in the summer of 2025. This amended protocol enrolls only platinum resistant or platinum-ineligible patients

and is designed to accelerate the clinical development of stenoparib toward FDA approval. In parallel, a separate Phase 2 trial evaluating

stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) began enrolling patients in early 2026 and is currently

enrolling patients across multiple U.S. Veterans Administration (VA) sites.

About the Drug Response Predictor – DRP®

Companion Diagnostic

Allarity uses its drug-specific DRP® to

select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific

drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the

therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines,

including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.

DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to

provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical

studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of

anti-cancer drugs, has been extensively published in the peer-reviewed literature.

Page 3 of 5

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is

a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development

of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to

develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib.

Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs

in cancer treatment. For more information, visit www.allarity.com.

Follow Allarity on Social Media

LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains “forward-looking

statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s

current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”

“possible,” “potential,” “predicts,” “project,” “should,” “would”

and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not

forward-looking. These forward-looking statements include, but are not limited to, statements regarding the publication and presentation

of data from the AACR 2026 Annual Meeting; the interpretation and significance of the data presented; the potential applicability of stenoparib

in colorectal cancer and other cancer indications; and the potential utility of the Company’s DRP® companion diagnostic platform.

Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject

to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied

by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the possibility that

the data presented may not be predictive of future clinical results; the risk that preclinical findings may not translate into clinical

benefit; the risk that the Company’s DRP® companion diagnostic may not be successfully developed, validated, or applied in future

clinical settings; and broader risks related to the Company’s clinical development, regulatory progress, and financial resources.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ

from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report

filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2026, available at the SEC’s website at www.sec.gov,

and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with

the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information

unless required by law.

###

Page 4 of 5

Company Contact:

investorrelations@allarity.com

Media Contact:

Thomas Pedersen

Carrotize PR & Communications

+45 6062 9390

tsp@carrotize.com

Page 5 of 5

GRAPHIC

Filename: ea028715601_ex99-1img1.jpg · Sequence: 3

Binary file (8674 bytes)

Download ea028715601_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 21, 2026

Entity File Number

001-41160

Entity Registrant Name

ALLARITY THERAPEUTICS, INC.

Entity Central Index Key

0001860657

Entity Tax Identification Number

87-2147982

Entity Incorporation, State or Country Code

Entity Address, Address Line One

123 E Tarpon Ave

Entity Address, City or Town

Tarpon Springs

Entity Address, State or Province

Entity Address, Postal Zip Code

34689

City Area Code

401

Local Phone Number

426-4664

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

ALLR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration